11 November 2021 
EMA/CHMP606839/2021 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Rapiscan 
regadenoson 
On 11 November 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Rapiscan. The marketing authorisation holder for this medicinal product is GE Healthcare AS. 
The CHMP adopted a change to the existing indication as follows:2  
This medicinal product is for diagnostic use only. 
Rapiscan is a selective coronary vasodilator for use in adults as a pharmacological stress agent 
for: 
• 
• 
radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate 
exercise stress. 
the measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during 
invasive coronary angiography, when repeated FFR measurements are not anticipated (see 
sections 4.2 and 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 Removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
